Sebelipase alfa

(Kanuma)

Sebelipase alfa

Drug updated on 11/16/2023

Dosage FormInjection (intravenous; 20 mg/10 mL)
Drug ClassMultiple
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency

Product Monograph / Prescribing Information

Document TitleYearSource
Kanuma (sebelipase alfa) Prescribing Information.2022Alexion Pharmaceuticals Inc., New Haven, CT

Systematic Reviews / Meta-Analyses